Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Agergaard, K, Mau-Sørensen, M, Stage, TB, Jørgensen, TL, Hassel, RE, Steffensen, KD, Pedersen, JW, Milo, M, Poulsen, SH, Pottegård, A, Hallas, J, Brøsen, K & Bergmann, TK 2017, 'Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study' Clinical Pharmacology and Therapeutics, bind 102, nr. 3, s. 547-553. https://doi.org/10.1002/cpt.674

APA

Agergaard, K., Mau-Sørensen, M., Stage, T. B., Jørgensen, T. L., Hassel, R. E., Steffensen, K. D., ... Bergmann, T. K. (2017). Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. Clinical Pharmacology and Therapeutics, 102(3), 547-553. https://doi.org/10.1002/cpt.674

CBE

Agergaard K, Mau-Sørensen M, Stage TB, Jørgensen TL, Hassel RE, Steffensen KD, Pedersen JW, Milo M, Poulsen SH, Pottegård A, Hallas J, Brøsen K, Bergmann TK. 2017. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. Clinical Pharmacology and Therapeutics. 102(3):547-553. https://doi.org/10.1002/cpt.674

MLA

Vancouver

Author

Agergaard, K ; Mau-Sørensen, M ; Stage, T B ; Jørgensen, T L ; Hassel, R E ; Steffensen, K D ; Pedersen, J W ; Milo, Mlh ; Poulsen, S H ; Pottegård, A ; Hallas, J ; Brøsen, K ; Bergmann, T K. / Clopidogrel-Paclitaxel Drug-Drug Interaction : A Pharmacoepidemiologic Study. I: Clinical Pharmacology and Therapeutics. 2017 ; Bind 102, Nr. 3. s. 547-553.

Bibtex

@article{f5ee5071c27a4c8fa914cba1103a86f7,
title = "Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study",
abstract = "Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin. By a cumulative dose of 1,500 mg paclitaxel, 35{\%} of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95{\%} confidence interval, 0.9-3.0). Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2.3 (95{\%} confidence interval, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel.",
keywords = "Aged, Aspirin, Cytochrome P-450 CYP2C8, Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Liver, Male, Middle Aged, Paclitaxel, Peripheral Nervous System Diseases, Pharmacoepidemiology, Platelet Aggregation Inhibitors, Retrospective Studies, Severity of Illness Index, Ticlopidine, Journal Article",
author = "K Agergaard and M Mau-S{\o}rensen and Stage, {T B} and J{\o}rgensen, {T L} and Hassel, {R E} and Steffensen, {K D} and Pedersen, {J W} and Mlh Milo and Poulsen, {S H} and A Potteg{\aa}rd and J Hallas and K Br{\o}sen and Bergmann, {T K}",
note = "{\circledC} 2017 American Society for Clinical Pharmacology and Therapeutics.",
year = "2017",
month = "9",
doi = "10.1002/cpt.674",
language = "English",
volume = "102",
pages = "547--553",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - Clopidogrel-Paclitaxel Drug-Drug Interaction

T2 - A Pharmacoepidemiologic Study

AU - Agergaard, K

AU - Mau-Sørensen, M

AU - Stage, T B

AU - Jørgensen, T L

AU - Hassel, R E

AU - Steffensen, K D

AU - Pedersen, J W

AU - Milo, Mlh

AU - Poulsen, S H

AU - Pottegård, A

AU - Hallas, J

AU - Brøsen, K

AU - Bergmann, T K

N1 - © 2017 American Society for Clinical Pharmacology and Therapeutics.

PY - 2017/9

Y1 - 2017/9

N2 - Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin. By a cumulative dose of 1,500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% confidence interval, 0.9-3.0). Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2.3 (95% confidence interval, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel.

AB - Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin. By a cumulative dose of 1,500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% confidence interval, 0.9-3.0). Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2.3 (95% confidence interval, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel.

KW - Aged

KW - Aspirin

KW - Cytochrome P-450 CYP2C8

KW - Dose-Response Relationship, Drug

KW - Drug Interactions

KW - Female

KW - Humans

KW - Liver

KW - Male

KW - Middle Aged

KW - Paclitaxel

KW - Peripheral Nervous System Diseases

KW - Pharmacoepidemiology

KW - Platelet Aggregation Inhibitors

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Ticlopidine

KW - Journal Article

U2 - 10.1002/cpt.674

DO - 10.1002/cpt.674

M3 - Journal article

VL - 102

SP - 547

EP - 553

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -

ID: 52073264